BeBetter Medicine is engaged in discovery and development of small molecule drugs for treating lymphoma, lung cancer , ovarian cancer, etc. Among its pipeline, BEBT-908 is a Class 1.1 dual target new drug against recurrent or refractory lymphoma. The company is based in Guanghzou, China.
